Document ID: FDA-2018-N-2727-0042
Agency: fda
Document Type: Proposed Rule
Title: Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations; Reopening of Comment Period
Posted Date: 2019-02-25T05:00Z

[Federal Register Volume 84, Number 37 (Monday, February 25, 2019)]
[Proposed Rules]
[Pages 5968-5969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03195]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 50, 312, and 812

[Docket No. FDA-2018-N-2727]
RIN 0910-AH52

Institutional Review Board Waiver or Alteration of Informed 
Consent for Minimal Risk Clinical Investigations; Reopening of Comment 
Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule; reopening of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is 
reopening the comment period for the proposed rule that appeared in the 
Federal Register of November 15, 2018. In the Federal Register of 
December 20, 2018, the Agency extended the comment period until 
February 13, 2019. The Agency is taking this action to reopen the 
comment period to allow interested persons additional time to submit 
comments due to technical issues with the Federal eRulemaking Portal 
(https://www.regulations.gov) on February 13, 2019.

DATES: FDA is reopening the comment period on the proposed rule 
published November 15, 2018 (83 FR 57378). Submit either electronic or 
written comments by March 7, 2019.

ADDRESSES: You may submit comments as follows. Please note that late, 
untimely filed comments will not be considered. Electronic comments 
must be submitted on or before March 7, 2019. The https://www.regulations.gov electronic filing system will accept comments until 
11:59 p.m. Eastern Time at the end of March 7, 2019. Comments received 
by mail/hand delivery/courier (for written/paper submissions) will be 
considered timely if they are postmarked or the delivery service 
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2018-N-2727 for ``Institutional Review Board Waiver or Alteration 
of Informed Consent for Minimal Risk Clinical Investigations.'' 
Received comments, those filed in a timely manner (see ADDRESSES), will 
be placed in the docket and, except for those submitted as 
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. 
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the

[[Page 5969]]

claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Janet Norden, Office of Good Clinical 
Practice, Food and Drug Administration, 10903 New Hampshire Ave., 
Silver Spring, MD 20993-0002, 301-796-1127.

SUPPLEMENTARY INFORMATION: In the Federal Register of November 15, 2018 
(83 FR 57378), FDA published a proposed rule with a 60-day comment 
period to implement the statutory changes made to the Federal Food, 
Drug, and Cosmetic Act by section 3024 of the 21st Century Cures Act 
(Pub. L. 114-255) to allow for a waiver or alteration of informed 
consent when a clinical investigation poses no more than minimal risk 
to the human subject and includes appropriate safeguards to protect the 
rights, safety, and welfare of human subjects. The proposed rule, if 
finalized, would permit an institutional review board (IRB) to waive or 
alter certain informed consent elements or to waive the requirement to 
obtain informed consent, under limited conditions, for certain minimal 
risk clinical investigations. Comments on the proposed rule will inform 
FDA's rulemaking to establish regulations for IRB waiver or alteration 
of informed consent for certain minimal risk clinical investigations.
    The Agency received a request for a 60-day extension of the comment 
period for the proposed rule. This request conveyed concern that the 
60-day comment period did not allow sufficient time to develop a 
meaningful or thoughtful response to the proposed rule. FDA considered 
the request and in the Federal Register of December 20, 2018 (83 FR 
65322), the Agency extended the comment period for the proposed rule 
for 30 days, until February 13, 2019. The Agency believed that a 30-day 
extension allowed adequate time for interested persons to submit 
comments without significantly delaying rulemaking on these important 
issues.
    On February 13, 2019, the date that the comment period closed for 
the proposed rule, the Federal eRulemaking Portal (https://www.regulations.gov) was unavailable to receive public comments from 
5:35 p.m. until 7:40 a.m. on February 14, 2019. The Agency is aware 
that interested persons attempted to submit comments during the period 
of time that https://www.regulations.gov was unavailable. Therefore, 
FDA is reopening the comment period for the proposed rule for 10 days, 
until March 7, 2019 to allow additional time for interested persons to 
submit comments.

    Dated: February 20, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
[FR Doc. 2019-03195 Filed 2-22-19; 8:45 am]
BILLING CODE 4164-01-P